incident. Within minutes of the seventh monthly maintenance dose (which belonged to the same batch as the previous doses), the patient experienced chest tightness, dizziness, and a rapid drop in blood pressure to 60/40 mmHg. He was premedicated with 50 mg of oral prednisone and 10 mg of loratadine for the next monthly dose, and the 100-µg dose was split between both arms, although he presented the same reaction as in the previous month. MC disease was then suspected. VIT was interrupted and a bone marrow study was performed to evaluate all the disease characteristics used for the diagnosis of SM. The study involved bone marrow MC cytology, histology, immunochemistry, flow cytometry immunophenotyping based on specific gating strategies for the detection of bone marrow MCs present at low frequencies, and the study of the KIT mutation in purified MCs [5] . A final diagnosis of indolent systemic mastocytosis without skin involvement (ISMs-) was reached, and the patient started therapy with disodium cromoglycate daily as part of the recommended treatment for this disease. In order to resume immunotherapy, he began with 300 mg of omalizumab every 4 weeks. After 2 doses, VIT was restarted without additional premedication and with good tolerance. The monoclonal antibody was maintained for a year-a little longer than the time elapsed in previous reactions with VIT-and a basophil activation test was performed before discontinuation, with negative results (Figure) . Most patients with mastocytosis are protected by VIT, although a minority may develop systemic adverse reactions after re-exposure. In this situation, it is recommended to increase the maintenance dose to 200 mg or more, since the degree of therapeutic success correlates with the dose of venom [6] . Furthermore, Api m 2 seemed to be the culprit allergen in the present case and has been considered a risk factor for systemic adverse reaction [7] . Given that the patient had not undergone field re-sting since the beginning of VIT, when we confirmed the decrease in sIgE values once the effect of omalizumab had disappeared (9 months, according to the manufacturer), SCT was performed according to the proposed methodology [4] without prompting a reaction.
Although the present study is based on only 1 case report, several relevant conclusions can be drawn. Patients presenting with anaphylaxis to hymenoptera stings are at high risk for clonal MC disorders [1] . Along with the determination of baseline serum tryptase in patients with anaphylaxis following hymenoptera stings, the clinical features of anaphylaxis should also be taken into account, since there is an association between the presence of cardiovascular symptoms in the absence of both urticaria and angioedema and ISMs-and clonal MC activation syndromes [8] . Furthermore, in ISMs-, MCs represent only a very small proportion of all nucleated bone marrow cells, and serum baseline tryptase levels are usually under reference values (<11.4 μg/L). The diagnosis of MC diseases requires the performance of a bone marrow biopsy, which is an expensive, Figure. Chronological summary of the study and allergology work-up. BAT indicates basophil activation test; BM, bone marrow; CCD, cross-reacting carbohydrate determinants; ISMs-, indolent systemic mastocytosis without skin lesions; n, native; NA, not available; r, recombinant; sIgE, specific immunoglobulin E; VIT, venom immunotherapy. 
